Microcap Ledger Ironwood Pharmaceuticals Inc $IRWD
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 165,239,947 [10-Q 2026-08-06]
What the company doesAI summary of filing
Ironwood Pharmaceuticals is a revenue-generating biotechnology company that develops and commercializes therapies for gastrointestinal and rare diseases. The company's primary product is LINZESS (linaclotide), a commercially available treatment for irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation, which generated $289.3 million in collaborative arrangements revenue in 2025. Through partnerships with AbbVie, AstraZeneca, and Astellas, LINZESS is marketed in the U.S., Europe, Canada, Mexico, Japan, and China. Ironwood is also advancing apraglutide, a GLP-2 analog in Phase III clinical trials for short bowel syndrome with intestinal failure, with a confirmatory trial expected to begin in the second quarter of 2026. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $219.55M | $92.06M | $63.40M | $79.13M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $296.15M | $24.02M | $127.04M | $215.46M | [10-K 2026-02-26] |
| FY ended Dec 2024 | $351.41M | $880.0K | $103.55M | $88.56M | [10-K 2026-02-26] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 160,028,388 | [10-Q 2024-11-07] |
| 2025-02-28 | 161,809,432 | [10-K 2025-03-31] |
| 2025-04-30 | 161,819,848 | [10-Q 2025-05-12] |
| 2025-07-31 | 162,434,130 | [10-Q 2025-08-11] |
| 2025-10-31 | 162,678,647 | [10-Q 2025-11-10] |
| 2026-01-31 | 163,058,316 | [10-K 2026-02-26] |
| 2026-04-30 | 164,613,406 | [10-Q 2026-05-07] |
| 2026-07-31 | 165,239,947 | [10-Q 2026-08-06] |
- Shelf registration
- S-3ASR filed 2023-11-09 [S-3ASR 2023-11-09]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-06-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-06-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-03] |
| 2025-03-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-27] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-15 | Denner Alexander J | grant | 3,694 | — | [4 2026-09-17] |
| 2026-07-20 | Silber Jeffrey | grant | 137,036 | — | [4 2026-07-22] |
| 2026-07-07 | Silver Ronald | sell | 127,890 | $4.52 | [4 2026-07-09] |
| 2026-06-16 | Shepard Jay | grant | 63,481 | — | [4 2026-06-17] |
| 2026-06-16 | Kessler Marla L | grant | 63,481 | — | [4 2026-06-17] |
| 2026-06-16 | Currie Mark G | grant | 63,481 | — | [4 2026-06-17] |
| 2026-06-16 | Duane Jon R | grant | 63,481 | — | [4 2026-06-17] |
| 2026-06-16 | Denner Alexander J | grant | 63,481 | — | [4 2026-06-17] |
| 2026-06-15 | Denner Alexander J | grant | 4,065 | — | [4 2026-06-17] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-28 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-18 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-15 | 8-K | Other events |
| 2026-05-21 | 8-K | Director or officer change |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 8-K | Director or officer change |
| 2026-05-07 | 10-Q | Quarterly report |
Alerts for $IRWD
Email me when Ironwood Pharmaceuticals Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.